Bupropion in the Treatment of Pathological Gambling
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00055393|
Recruitment Status : Completed
First Posted : March 3, 2003
Last Update Posted : March 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pathological Gambling||Drug: Bupropion Drug: Placebo||Not Applicable|
As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.
Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Bupropion Versus Placebo in the Treatment of Pathological Gambling|
|Study Start Date :||July 2002|
|Actual Primary Completion Date :||May 2005|
|Actual Study Completion Date :||April 2006|
Active Comparator: Subjects receivng Bupropion
The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
18 subjects in this randomly controlled double blind study received bupropion.
Placebo Comparator: Subjects receiving Placebo
The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
21 subjects received Placebo.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00055393
|United States, Iowa|
|Roy J. and Lucille A. Carver College of Medicine, University of Iowa|
|Iowa City, Iowa, United States, 52242|
|Principal Investigator:||Donald W Black, MD||University of Iowa|